{"doi":"10.1093\/annonc","coreId":"51481","oai":"oai:eprints.lincoln.ac.uk:4340","identifiers":["oai:eprints.lincoln.ac.uk:4340","10.1093\/annonc"],"title":"The impact of pre-treatment haemoglobin and tumour length of disease free survival and local recurrence in rectal cancers treated with preoperative chemo-radiotherapy","authors":["Amrou, S.","Khan, A.","Klonizakis, Markos","Anyamene, N.","Mawdsley, S.","Denton, A.","Hughes, R.","Harrison, M.","Glynnes-Jones, R."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2010-07","abstract":"Background: Pre-operative chemoradiotherapy prior to surgery has become\\ud\na mainstay of treatment for rectal cancers with threatened surgical margins. Many trials\\ud\nusing different chemo\/ radiotherapy regimes, have examined various predictive and\\ud\nprognostic factors [1-4]. We aimed to assess the impact of pre-treatment haemoglobin\\ud\n(Hb) and length of the rectal tumour (clinically and radiologically) on 3-year disease\\ud\nfree survival and local recurrence in our patient population.\\ud\nMethods: We have prospectively collected data on all consecutive patients with\\ud\nhistologically confirmed adenocarcinoma of the rectum treated with pre-operative\\ud\nradiotherapy or chemoradiotherapy at the Mount Vernon Cancer Centre (MVCC) between March 1994 and December 2008. MRI staging has been routine since 1997.\\ud\nThis included data on patient demographics, presenting symptoms, (anaemia, rectal\\ud\nbleeding), tumour stage (TNM Classification), differentiation, treatment regime (5FU,\\ud\ncapecitabine or two cytotoxic drugs), toxicity and outcomes (3 year disease free\\ud\nsurvival). Haemoglobin level of 10g\/dL or above was considered normal. Tumour\\ud\nlength was measured clinically using rectal examination, CT scan and by MRI (for\\ud\npatients after 1997). Differences between populations were assessed using the chisquared\\ud\ntest, and survival analyses were performed using the Kaplan-Meier method\\ud\nand the logrank test. In addition, a survival analysis was performed implementing\\ud\na Cox Regression with Backwards Stepwise (Wald) Regression re-evaluating the\\ud\npotential prognostic factors found to be significant in univariate analysis. All analyses\\ud\nwere carried out using SPSS 14.0 (SPSS, USA).\\ud\nResults: Three hundred and eighty four patients were eligible for our analysis. Median\\ud\nage of diagnosis was 66 years; male:female ratio was 65:35. 191 were treated with\\ud\na concurrent treatment regimen consisting of 5FU\/ folinic acid, 134 with Capecitabine, 18\\ud\nwith short course radiotherapy and 41 with combinations of 2 cytotoxics. Of the 384\\ud\npatients, 20 had presenting pre-treatment Hb below 10 g\/dL. On univariate analysis, Hb\\ud\nwas related to tumor length (p=0.02, eta square=0.03) and tumor T stage (p<0.01, eta\\ud\nsquare=0.04) but not the lymph node status (p=0.568, eta square=0.01). Eta square (used\\ud\nas an indication of the effect size) for the final model is 0.08 which reflects a moderate\\ud\nstrength. After undertaking a Cox-Regression Survival Analysis, neither Hb nor tumour\\ud\nlength showed any relation with 3 year disease free survival whereas treatment regime\\ud\n(0.933 general exp. and p=0.01) and T Stage with patients being at stage 4 being at greater\\ud\nrisk (p=0.027 and exp. 0.604 vs p=0.405 and exp. 0.706 for those at stage 3) showed\\ud\nsignificant impact. As for local recurrence, again Hb (p=0.150) and the tumour length\\ud\n(p=0.676) showed no relation, however, T Stage was the most significant determinant as\\ud\nof whether local recurrence occurred or not (p=0.04 with exp 2.132).\\ud\nConclusions: Contrary to previous studies [2, 3], our series does not show any relation\\ud\nbetween Hb and\/or tumour length on 3 year disease free survival and local recurrence.\\ud\nTumour stage remains the most significant determinant in predicting whether local recurrence occurred or not","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Oxford University Press on behalf of the European Society for Medical Oncology","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lincoln.ac.uk:4340<\/identifier><datestamp>\n      2013-03-13T08:58:45Z<\/datestamp><setSpec>\n      7374617475733D707562<\/setSpec><setSpec>\n      7375626A656374733D6A6163735F41:6A6163735F41333030<\/setSpec><setSpec>\n      74797065733D61727469636C65<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lincoln.ac.uk\/4340\/<\/dc:relation><dc:title>\n        The impact of pre-treatment haemoglobin and tumour length of disease free survival and local recurrence in rectal cancers treated with preoperative chemo-radiotherapy<\/dc:title><dc:creator>\n        Amrou, S.<\/dc:creator><dc:creator>\n        Khan, A.<\/dc:creator><dc:creator>\n        Klonizakis, Markos<\/dc:creator><dc:creator>\n        Anyamene, N.<\/dc:creator><dc:creator>\n        Mawdsley, S.<\/dc:creator><dc:creator>\n        Denton, A.<\/dc:creator><dc:creator>\n        Hughes, R.<\/dc:creator><dc:creator>\n        Harrison, M.<\/dc:creator><dc:creator>\n        Glynnes-Jones, R.<\/dc:creator><dc:subject>\n        A300 Clinical Medicine<\/dc:subject><dc:description>\n        Background: Pre-operative chemoradiotherapy prior to surgery has become\\ud\na mainstay of treatment for rectal cancers with threatened surgical margins. Many trials\\ud\nusing different chemo\/ radiotherapy regimes, have examined various predictive and\\ud\nprognostic factors [1-4]. We aimed to assess the impact of pre-treatment haemoglobin\\ud\n(Hb) and length of the rectal tumour (clinically and radiologically) on 3-year disease\\ud\nfree survival and local recurrence in our patient population.\\ud\nMethods: We have prospectively collected data on all consecutive patients with\\ud\nhistologically confirmed adenocarcinoma of the rectum treated with pre-operative\\ud\nradiotherapy or chemoradiotherapy at the Mount Vernon Cancer Centre (MVCC) between March 1994 and December 2008. MRI staging has been routine since 1997.\\ud\nThis included data on patient demographics, presenting symptoms, (anaemia, rectal\\ud\nbleeding), tumour stage (TNM Classification), differentiation, treatment regime (5FU,\\ud\ncapecitabine or two cytotoxic drugs), toxicity and outcomes (3 year disease free\\ud\nsurvival). Haemoglobin level of 10g\/dL or above was considered normal. Tumour\\ud\nlength was measured clinically using rectal examination, CT scan and by MRI (for\\ud\npatients after 1997). Differences between populations were assessed using the chisquared\\ud\ntest, and survival analyses were performed using the Kaplan-Meier method\\ud\nand the logrank test. In addition, a survival analysis was performed implementing\\ud\na Cox Regression with Backwards Stepwise (Wald) Regression re-evaluating the\\ud\npotential prognostic factors found to be significant in univariate analysis. All analyses\\ud\nwere carried out using SPSS 14.0 (SPSS, USA).\\ud\nResults: Three hundred and eighty four patients were eligible for our analysis. Median\\ud\nage of diagnosis was 66 years; male:female ratio was 65:35. 191 were treated with\\ud\na concurrent treatment regimen consisting of 5FU\/ folinic acid, 134 with Capecitabine, 18\\ud\nwith short course radiotherapy and 41 with combinations of 2 cytotoxics. Of the 384\\ud\npatients, 20 had presenting pre-treatment Hb below 10 g\/dL. On univariate analysis, Hb\\ud\nwas related to tumor length (p=0.02, eta square=0.03) and tumor T stage (p<0.01, eta\\ud\nsquare=0.04) but not the lymph node status (p=0.568, eta square=0.01). Eta square (used\\ud\nas an indication of the effect size) for the final model is 0.08 which reflects a moderate\\ud\nstrength. After undertaking a Cox-Regression Survival Analysis, neither Hb nor tumour\\ud\nlength showed any relation with 3 year disease free survival whereas treatment regime\\ud\n(0.933 general exp. and p=0.01) and T Stage with patients being at stage 4 being at greater\\ud\nrisk (p=0.027 and exp. 0.604 vs p=0.405 and exp. 0.706 for those at stage 3) showed\\ud\nsignificant impact. As for local recurrence, again Hb (p=0.150) and the tumour length\\ud\n(p=0.676) showed no relation, however, T Stage was the most significant determinant as\\ud\nof whether local recurrence occurred or not (p=0.04 with exp 2.132).\\ud\nConclusions: Contrary to previous studies [2, 3], our series does not show any relation\\ud\nbetween Hb and\/or tumour length on 3 year disease free survival and local recurrence.\\ud\nTumour stage remains the most significant determinant in predicting whether local recurrence occurred or not.<\/dc:description><dc:publisher>\n        Oxford University Press on behalf of the European Society for Medical Oncology<\/dc:publisher><dc:date>\n        2010-07<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:format>\n        application\/pdf<\/dc:format><dc:language>\n        en<\/dc:language><dc:identifier>\n        http:\/\/eprints.lincoln.ac.uk\/4340\/1\/Annals_2010.pdf<\/dc:identifier><dc:identifier>\n          Amrou, S. and Khan, A. and Klonizakis, Markos and Anyamene, N. and Mawdsley, S. and Denton, A. and Hughes, R. and Harrison, M. and Glynnes-Jones, R.  (2010) The impact of pre-treatment haemoglobin and tumour length of disease free survival and local recurrence in rectal cancers treated with preoperative chemo-radiotherapy.  Annals of Oncology, 21  (Supple).   pp. 159-160.  ISSN 0923-7534  <\/dc:identifier><dc:relation>\n        http:\/\/dx.doi.org\/10.1093\/annonc\/mdq270<\/dc:relation><dc:relation>\n        10.1093\/annonc\/mdq270<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lincoln.ac.uk\/4340\/","http:\/\/dx.doi.org\/10.1093\/annonc\/mdq270","10.1093\/annonc\/mdq270"],"year":2010,"topics":["A300 Clinical Medicine"],"subject":["Article","PeerReviewed"],"fullText":null}